LENZ Therapeutics, Inc. (LENZ)Healthcare | Biotechnology | Solana Beach, United States | NasdaqGS
3.62 USD
+0.18
(5.386%)
⇧
(Oct. 15, 2026, 3:04 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:51 a.m. EDT
The investment case here is fundamentally broken. LENZ Therapeutics is a biotech company burning through cash with no revenue, posting significant losses, and facing a severe liquidity crisis. The balance sheet is precarious; while cash on hand looks decent on paper, the company is hemorrhaging operating cash flow and free cash flow, with analysts actively trimming growth assumptions and resetting fair value lower. The stock has already suffered a catastrophic multi-year decline, dropping nearly 80% from its peak, reflecting the market's harsh verdict on the business model. The most alarming signal is the options activity, which screams 'sell' or 'hedge against collapse.' Traders are buying deep out-of-the-money puts in record numbers, betting on a continued freefall, while call speculation is virtually non-existent beyond the immediate vicinity. This confirms that even the most optimistic speculators see little room for upside in the near term. Regarding the dividend, there is none. The recent payments listed in the data appear to be anomalies or errors given the company's reported negative free cash flow and lack of profitability; a biotech firm in this stage of development cannot sustainably pay dividends without eroding capital needed for R&D. Relying on such a payout would be a fatal mistake. In short, this is a high-risk speculative vehicle with deteriorating fundamentals and a market that is pricing in further distress. Avoid. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.081878 |
| MSTL | 0.082954 |
| AutoETS | 0.084396 |
| AutoARIMA | 0.194265 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 3.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.009 |
| Excess Kurtosis | 0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2024-03-21 |
| Debt to Equity Ratio | 0.26 |
| Revenue per Share | 0.702 |
| Market Cap | 113,584,544 |
| Forward P/E | -1.24 |
| Beta | 1.73 |
| Website | https://www.lenz-tx.com |
As of Oct. 10, 2026, 6:51 a.m. EDT: Speculators are aggressively positioning for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes 10.00, 12.50, 15.00) where volume significantly exceeds existing open interest. Conversely, call activity is concentrated in the money or slightly out-of-the-money, with very little speculative volume in strikes far above current prices. This imbalance suggests a market consensus expecting further weakness rather than a catalyst-driven rally.
| Date | Dividend | Yield % |
|---|---|---|
| 2024-03-22 | 7.21 | 44.506171 |
| 2024-03-15 | 7.21 | 30.838324 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9152039 |
| Address1 | 201 Lomas Santa Fe Drive |
| Address2 | Suite 300 |
| All Time High | 238.0 |
| All Time Low | 3.345 |
| Ask | 4.4 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 774,770 |
| Average Daily Volume3 Month | 793,529 |
| Average Volume | 793,529 |
| Average Volume10Days | 774,770 |
| Beta | 1.73 |
| Bid | 2.6 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 6.979 |
| City | Solana Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.615 |
| Current Ratio | 13.553 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.62 |
| Day Low | 3.43 |
| Debt To Equity | 0.26 |
| Display Name | LENZ Therapeutics |
| Dividend Date | 1,710,979,200 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,480,200 |
| Earnings Call Timestamp Start | 1,786,480,200 |
| Earnings Timestamp | 1,786,478,400 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -135,204,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.826 |
| Enterprise To Revenue | -5.2 |
| Enterprise Value | -111,662,224 |
| Eps Current Year | -4.20333 |
| Eps Forward | -2.91167 |
| Eps Trailing Twelve Months | -4.17 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.4874 |
| Fifty Day Average Change | -0.87240005 |
| Fifty Day Average Change Percent | -0.19441102 |
| Fifty Two Week Change Percent | -91.52039 |
| Fifty Two Week High | 42.98 |
| Fifty Two Week High Change | -39.364998 |
| Fifty Two Week High Change Percent | -0.91589105 |
| Fifty Two Week Low | 3.345 |
| Fifty Two Week Low Change | 0.26999998 |
| Fifty Two Week Low Change Percent | 0.08071748 |
| Fifty Two Week Range | 3.345 - 42.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,624,627,800,000 |
| Float Shares | 18,393,155 |
| Forward Eps | -2.91167 |
| Forward P E | -1.2415556 |
| Free Cashflow | -71,252,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 152 |
| Fullday Change | 0.18499994 |
| Fullday Change Percent | 5.3857336 |
| Fullday Price | 3.615 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.91739 |
| Gross Profits | 19,701,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02648 |
| Held Percent Institutions | 1.11489 |
| Implied Shares Outstanding | 31,420,343 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,711,065,600 |
| Last Dividend Value | 7.21 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,711,065,600 |
| Last Split Factor | 1:7 |
| Long Business Summary | LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California. |
| Long Name | LENZ Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 113,584,544 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_370131860 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -126,002,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 118,140,489 |
| Number Of Analyst Opinions | 7 |
| Open | 3.43 |
| Operating Cashflow | -113,908,000 |
| Operating Margins | -6.22895 |
| Overall Risk | 8 |
| Phone | 858 925 7000 |
| Previous Close | 3.43 |
| Price Eps Current Year | -0.8600324 |
| Price Hint | 4 |
| Price To Book | 0.51798254 |
| Price To Sales Trailing12 Months | 5.289152 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.906 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.57143 |
| Region | US |
| Regular Market Change | 0.18499994 |
| Regular Market Change Percent | 5.3857336 |
| Regular Market Day High | 3.62 |
| Regular Market Day Low | 3.43 |
| Regular Market Day Range | 3.43 - 3.62 |
| Regular Market Open | 3.43 |
| Regular Market Previous Close | 3.43 |
| Regular Market Price | 3.615 |
| Regular Market Time | 1,792,091,064 |
| Regular Market Volume | 524,631 |
| Return On Assets | -0.37355998 |
| Return On Equity | -0.59208 |
| Revenue Growth | 0.097 |
| Revenue Per Share | 0.702 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 31,420,343 |
| Shares Percent Shares Out | 0.3361 |
| Shares Short | 10,560,869 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 10,874,649 |
| Short Name | LENZ Therapeutics, Inc. |
| Short Percent Of Float | 0.5529 |
| Short Ratio | 13.99 |
| Source Interval | 15 |
| State | CA |
| Symbol | LENZ |
| Target High Price | 60.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 23.85714 |
| Target Median Price | 10.0 |
| Total Cash | 220,003,008 |
| Total Cash Per Share | 7.002 |
| Total Debt | 569,000 |
| Total Revenue | 21,475,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.17 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.799925 |
| Two Hundred Day Average Change | -5.184925 |
| Two Hundred Day Average Change Percent | -0.5892011 |
| Type Disp | Equity |
| Volume | 524,631 |
| Website | https://www.lenz-tx.com |
| Zip | 92,075 |